Takeda Pharmaceutical Company Ltd
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 105
- Registration Number
- NCT01496430
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2454
- Registration Number
- NCT01481116
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 184
- Registration Number
- NCT01478971
- Locations
- πΊπΈ
Research Facility, San Antonio, Texas, United States
Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease
Phase 3
Completed
- Conditions
- Non-erosive Gastroesophageal Reflux Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 827
- Registration Number
- NCT01474369
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 642
- Registration Number
- NCT01467713
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 490
- Registration Number
- NCT01467700
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 607
- Registration Number
- NCT01459367
Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
Phase 2
Completed
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 487
- Registration Number
- NCT01458301
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Phase 3
Completed
- Conditions
- Gastric UlcersDuodenal Ulcers
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 406
- Registration Number
- NCT01456260
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
Phase 3
Completed
- Conditions
- Gastric UlcersDuodenal Ulcers
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 439
- Registration Number
- NCT01456247
Β© Copyright 2025. All Rights Reserved by MedPath